These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18393849)

  • 21. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page MM; Hooper AJ; Burnett JR
    Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.
    Chait A; Goldberg I
    Curr Diab Rep; 2017 Sep; 17(11):112. PubMed ID: 28956258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Drugs for Atherosclerosis.
    Bruikman CS; Stoekenbroek RM; Hovingh GK; Kastelein JP
    Can J Cardiol; 2017 Mar; 33(3):350-357. PubMed ID: 27993452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors.
    Tavridou A; Manolopoulos VG
    Curr Pharm Des; 2009; 15(27):3167-78. PubMed ID: 19754389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
    Kones R; Rumana U
    Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Therapeutic Approaches to the Treatment of Dyslipidemia.
    Rader DJ
    Cell Metab; 2016 Mar; 23(3):405-12. PubMed ID: 26853751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cholesterol metabolism modulators in future drug therapy for atherosclerosis].
    Morozova S; Suc-Royer I; Auwerx J
    Med Sci (Paris); 2005 Dec; 21 Spec No():53-8. PubMed ID: 16598906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Looking into the crystal ball-upcoming drugs for dyslipidemia.
    George M; Selvarajan S; Muthukumar R; Elangovan S
    J Cardiovasc Pharmacol Ther; 2015 Jan; 20(1):11-20. PubMed ID: 25079474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and emerging drugs for the treatment of atherosclerosis: the evidence to date.
    Rizvi AA; Popovic DS; Papanas N; Pantea Stoian A; Al Mahmeed W; Sahebkar A; Janez A; Rizzo M
    Expert Rev Cardiovasc Ther; 2022 Jul; 20(7):515-527. PubMed ID: 35786159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
    ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dyslipidemia management update.
    Chang Y; Robidoux J
    Curr Opin Pharmacol; 2017 Apr; 33():47-55. PubMed ID: 28527325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential peptides in atherosclerosis therapy.
    Marleau S; Mellal K; Huynh DN; Ong H
    Front Horm Res; 2014; 43():93-106. PubMed ID: 24943301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.